A Study to Evaluate Lanraplenib (LANRA) in Combination With Gilteritinib in Participants With FLT3-mutated Relapsed or Refractory Acute Myeloid Leukemia (AML)

NCT05028751 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

TERMINATED

Status

24

Enrollment

INDUSTRY

Sponsor class

Stopped Sponsor decision

Conditions

Acute Myeloid Leukemia
Relapsed Acute Myeloid Leukemia
Refractory Acute Myeloid Leukemia

Interventions

DRUG: Lanraplenib
DRUG: Gilteritinib

Sponsor

Kronos Bio